|
1
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Castaigne S, Chomienne C, Daniel MT,
Ballerini P, Berger R, Fenaux P and Degos L: All-trans retinoic
acid as a differentiation therapy for acute promyelocytic leukemia.
I. Clinical results. Blood. 76:1704–1709. 1990.PubMed/NCBI
|
|
4
|
Chen Z, Tong JH, Dong S, Zhu J, Wang ZY
and Chen SJ: Retinoic acid regulatory pathways, chromosomal
translocations and acute promyelocytic leukemia. Genes Chromosomes
Cancer. 15:147–156. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones ME and Saleem A: Acute promyelocytic
leukemia. A review of literature. Am J Med. 65:673–677. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cunningham I, Gee TS, Reich LM, Kempin SJ,
Naval AN and Clarkson BD: Acute promyelocytic leukemia: Treatment
results during a decade at Memorial Hospital. Blood. 73:1116–1122.
1989.PubMed/NCBI
|
|
7
|
Sanz MA, Jarque I, Martin G, Lorenzo I,
Martínez J, Rafecas J, Pastor E, Sayas MJ, Sanz G and Gomis F:
Acute promyelocytic leukemia. Therapy results and prognostic
factors. Cancer. 61:7–13. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fenaux P, Wang ZZ and Degos L: Treatment
of acute promyelocytic leukemia by retinoids. Curr Top Microbiol
Immunol. 313:101–128. 2007.PubMed/NCBI
|
|
9
|
Kamimura T, Miyamoto T, Harada M and
Akashi K: Advances in therapies for acute promyelocytic leukemia.
Cancer Sci. 102:1929–1937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Looi CY, Arya A, Cheah FK, Muharram B,
Leong KH, Mohamad K, Wong WF, Rai N and Mustafa MR: Induction of
apoptosis in human breast cancer cells via caspase pathway
byvernodalol isolated from Centratherum anthelminticum (L.) seeds.
PLoS One. 8:e566432013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sadagopan SK Ananda, Mohebali N, Looi CY,
Hasanpourghadi M, Pandurangan AK, Arya A, Karimian H and Mustafa
MR: Forkhead box transcription factor (FOXO3a) mediates the
cytotoxic effect ofvernodalol in vitro and inhibits the breast
tumor growth in vivo. J Exp Clin Cancer Res. 34:1472015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ashok P, Koti BC, Thippeswamy AH, Tikare
VP, Dabadi P and Viswanathaswamy AH: Evaluation of antiinflammatory
activity of Centratherum anthelminticum (L) Kuntze seed. Indian J
Pharm Sci. 72:697–703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Purnima A, Koti BC, Tikare VP,
Viswanathaswamy AH, Thippeswamy AH and Dabadi P: Evaluation of
analgesic and antipyretic activities of Centratherum anthelminticum
(L) Kuntze seed. Indian J Pharm Sci. 71:461–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma S and Mehta BK: In vitro
antimicrobial efficacy of Centratherum anthelminticum seeds
extracts. J Hyg Epidemiol Microbiol Immunol. 35:157–161.
1991.PubMed/NCBI
|
|
15
|
Singhal KC, Sharma S and Mehta BK:
Antifilarial activity of Centratherum anthelminticum seed extracts
on Setaria cervi. Indian J Exp Biol. 30:546–548. 1992.PubMed/NCBI
|
|
16
|
Arya A, Achoui M, Cheah SC, Abdelwahab SI,
Narrima P, Mohan S, Mustafa MR and Mohd MA: Chloroform fraction of
Centratherum anthelminticum (L.) seed inhibits tumor necrosis
factor alpha and exhibits pleotropic bioactivities: Inhibitory role
in human tumor cells. Evid Based Complement Alternat Med.
2012:6272562012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petrie K, Zelent A and Waxman S:
Differentiation therapy of acute myeloid leukemia: Past, present
and future. Curr Opin Hematol. 16:84–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rabe T, Mullholland D and van Staden J:
Isolation and identification of antibacterial compounds from
Vernonia colorata leaves. J Ethnopharmacol. 80:91–94. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Looi CY, Moharram B, Paydar M, Wong YL,
Leong KH, Mohamad K, Arya A, Wong WF and Mustafa MR: Induction of
apoptosis in melanoma A375 cells by a chloroform fraction of
Centratherum anthelminticum (L.) seeds involves NF-kappaB, p53 and
Bcl-2-controlled mitochondrial signaling pathways. BMC Complement
Altern Med. 13:1662013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kasim LS, Ferro V, Odukoya OA, Ukpo GE,
Seidel V, Gray AI and Waigh R: Cytotoxicity of isolated compounds
from the extracts of Struchium sparganophora (Linn) Ktze
asteraceae. Pak J Pharm Sci. 24:475–478. 2011.PubMed/NCBI
|
|
22
|
Kupchan SM, Hemingway RJ, Karim A and
Werner D: Tumor inhibitors. XLVII. Vernodalol and vernomygdin, two
new cytotoxic sesquiterpene lactones from Vernonia amygdalina Del.
J Org Chem. 34:3908–3911. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Drexler HG: Review of alterations of the
cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18
and p19 in human leukemia-lymphoma cells. Leukemia. 12:845–859.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan MH, Lin CL, Tsai JH, Ho CT and Chen
WJ: 3,5,3′,4′, 5′-pentamethoxystilbene (MR-5), a synthetically
methoxylated analogue of resveratrol, inhibits growth and induces
G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J Agric
Food Chem. 58:226–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weir NM, Selvendiran K, Kutala VK, Tong L,
Vishwanath S, Rajaram M, Tridandapani S, Anant S and Kuppusamy P:
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant
human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer
Biol Ther. 6:178–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Furnari B, Blasina A, Boddy MN, McGowan CH
and Russell P: Cdc25 inhibited in vivo and in vitro by checkpoint
kinases Cds1 and Chk1. Mol Biol Cell. 10:833–845. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Innocente SA, Abrahamson JL, Cogswell JP
and Lee JM: p53 regulates a G2 checkpoint through cyclin B1. Proc
Natl Acad Sci USA. 96:pp. 2147–2152. 1999; View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McConkey DJ and Orrenius S: Signal
transduction pathways in apoptosis. Stem Cells. 14:619–311. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han S, Zhang G, Li M, Chen D, Wang Y, Ye W
and Ji Z: L-securinine induces apoptosis in the human promyelocytic
leukemia cell line HL-60 and influences the expression of genes
involved in the PI3K/AKT/mTOR signaling pathway. Oncol Rep.
31:2245–2251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hildebrandt MA, Yang H, Hung MC, Izzo JG,
Huang M, Lin J, Ajani JA and Wu X: Genetic variations in the
PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in
esophageal cancer patients treated with chemoradiotherapy. J Clin
Oncol. 27:857–871. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma W, Wang DD, Li L, Feng YK, Gu HM, Zhu
GM, Piao JH, Yang Y, Gao X and Zhang PX: Caveolin-1 plays a key
role in the oleanolic acid-induced apoptosis of HL-60 cells. Oncol
Rep. 32:293–301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Burgering BM and Coffer PJ: Protein kinase
B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
Nature. 376:599–602. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wick MJ, Dong LQ, Riojas RA, Ramos FJ and
Liu F: Mechanism of phosphorylation of protein kinase B/Akt by a
constitutively active 3-phosphoinositide-dependent protein
kinase-1. J Biol Chem. 275:40400–40406. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aoki M, Blazek E and Vogt PK: A role of
the kinase mTOR in cellular transformation induced by the
oncoproteins P3k and Akt. Proc Natl Acad Sci USA. 98:pp. 136–141.
2001; View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ali IU, Schriml LM and Dean M: Mutational
spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid
phosphatase activity. J Natl Cancer Inst. 91:1922–1932. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
